Keywords: phase, iii, results, zeneca, tomudex, presented, study

Phase III Results With Zeneca's Tomudex

Article | 24 July 1995

Print This

Zeneca has presented the results of a Phase III study of its specific thymidylate synthase inhibitor, Tomudex (ZD1694), at the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in